Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation - PubMed (original) (raw)
Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation
Daniëlle Horst et al. J Immunol. 2009.
Abstract
EBV persists for life in the human host while facing vigorous antiviral responses that are induced upon primary infection. This persistence supports the idea that herpesviruses have acquired dedicated functions to avoid immune elimination. The recently identified EBV gene product BNLF2a blocks TAP. As a result, reduced amounts of peptides are transported by TAP from the cytoplasm into the endoplasmic reticulum (ER) lumen for binding to newly synthesized HLA class I molecules. Thus, BNLF2a perturbs detection by cytotoxic T cells. The 60-aa-long BNLF2a protein prevents the binding of both peptides and ATP to TAP, yet further mechanistic insight is, to date, lacking. In this study, we report that EBV BNLF2a represents a membrane-associated protein that colocalizes with its target TAP in subcellular compartments, primarily the ER. In cells devoid of TAP, expression levels of BNLF2a protein are greatly diminished, while ER localization of the remaining BNLF2a is retained. For interactions of BNLF2a with the HLA class I peptide-loading complex, the presence of TAP2 is essential, whereas tapasin is dispensible. Importantly, we now show that in B cells supporting EBV lytic replication, the BNLF2a protein is expressed early in infection, colocalizing and associating with the peptide-loading complex. These results imply that, during productive EBV infection, BNLF2a contributes to TAP inhibition and surface HLA class I down-regulation. In this way, EBV BNLF2a-mediated evasion from HLA class I-restricted T cell immunity contributes to creating a window for undetected virus production.
Similar articles
- EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.
Horst D, Favaloro V, Vilardi F, van Leeuwen HC, Garstka MA, Hislop AD, Rabu C, Kremmer E, Rickinson AB, High S, Dobberstein B, Ressing ME, Wiertz EJ. Horst D, et al. J Immunol. 2011 Mar 15;186(6):3594-605. doi: 10.4049/jimmunol.1002656. Epub 2011 Feb 4. J Immunol. 2011. PMID: 21296983 - Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD. Croft NP, et al. PLoS Pathog. 2009 Jun;5(6):e1000490. doi: 10.1371/journal.ppat.1000490. Epub 2009 Jun 26. PLoS Pathog. 2009. PMID: 19557156 Free PMC article. - Epstein-Barr viral BNLF2a protein hijacks the tail-anchored protein insertion machinery to block antigen processing by the transport complex TAP.
Wycisk AI, Lin J, Loch S, Hobohm K, Funke J, Wieneke R, Koch J, Skach WR, Mayerhofer PU, Tampé R. Wycisk AI, et al. J Biol Chem. 2011 Dec 2;286(48):41402-41412. doi: 10.1074/jbc.M111.237784. Epub 2011 Oct 7. J Biol Chem. 2011. PMID: 21984826 Free PMC article. - Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ. Ressing ME, et al. Semin Cancer Biol. 2008 Dec;18(6):397-408. doi: 10.1016/j.semcancer.2008.10.008. Epub 2008 Oct 25. Semin Cancer Biol. 2008. PMID: 18977445 Review. - The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing.
Abele R, Tampé R. Abele R, et al. Physiology (Bethesda). 2004 Aug;19:216-24. doi: 10.1152/physiol.00002.2004. Physiology (Bethesda). 2004. PMID: 15304636 Review.
Cited by
- pUS6 in pseudorabies virus participates in the process of inhibiting antigen presentation by inhibiting the assembly of peptide loading complex.
Ma N, Sun Y, Ding C, Li Y, Yu L, Chen L. Ma N, et al. BMC Vet Res. 2024 Oct 9;20(1):454. doi: 10.1186/s12917-024-04294-3. BMC Vet Res. 2024. PMID: 39379944 Free PMC article. - The Role of NK Cells in EBV Infection and Related Diseases: Current Understanding and Hints for Novel Therapies.
Desimio MG, Covino DA, Rivalta B, Cancrini C, Doria M. Desimio MG, et al. Cancers (Basel). 2023 Mar 22;15(6):1914. doi: 10.3390/cancers15061914. Cancers (Basel). 2023. PMID: 36980798 Free PMC article. Review. - HLA-Bw4 in association with KIR3DL1 favors natural killer cell-mediated protection against severe COVID-19.
Wang R, Sun Y, Kuang BH, Yan X, Lei J, Lin YX, Tian J, Li Y, Xie X, Chen T, Zhang H, Zeng YX, Zhao J, Feng L. Wang R, et al. Emerg Microbes Infect. 2023 Dec;12(1):2185467. doi: 10.1080/22221751.2023.2185467. Emerg Microbes Infect. 2023. PMID: 36849422 Free PMC article. - Functional Implications of Epstein-Barr Virus Lytic Genes in Carcinogenesis.
Yap LF, Wong AKC, Paterson IC, Young LS. Yap LF, et al. Cancers (Basel). 2022 Nov 24;14(23):5780. doi: 10.3390/cancers14235780. Cancers (Basel). 2022. PMID: 36497262 Free PMC article. Review. - CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules.
Wu Y, Shrestha P, Heape NM, Yarchoan R. Wu Y, et al. J Transl Med. 2022 May 13;20(1):217. doi: 10.1186/s12967-022-03400-z. J Transl Med. 2022. PMID: 35562811 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous